Foundational guide
GLP-1 microdosing: a definitions-first guide
No universal definition — the distinct dose concepts, what the evidence supports, the risks, and the costs.
'Microdosing' a GLP-1 means using semaglutide or tirzepatide below its labeled maintenance dose, but there is no agreed clinical definition. It is distinct from starter dosing, slower titration, reduced maintenance, less-frequent dosing, and tapering — each of which has different evidence. This guide defines each concept and states what is and isn't supported.
Why there is no universal definition
The pivotal trials that established GLP-1 weight loss used specific therapeutic doses. 'Microdosing' is a wellness-market term applied afterward to a range of below-maintenance approaches. Because no standards body defines it, two 'microdose' programs can differ several-fold in actual milligrams.
That ambiguity is why this guide refuses to give a single chart and instead names the exact concept in play on every page — the difference between them is the difference between what is evidenced and what is marketing.
The distinct concepts
- FDA-labeled starter dose. The specific low initial dose in an FDA-approved product's prescribing information, used at treatment initiation to improve tolerability before titration. Evidence: Defined in FDA labeling; efficacy/safety established for the approved product only.
- Lower-than-maintenance dose. Any dose below a product's labeled maintenance dose, whether during titration or deliberately held below maintenance. Evidence: Not a standardized clinical protocol; outcomes at sub-maintenance doses are not established for weight management.
- Reduced maintenance dose. A maintenance dose intentionally set below the maximum studied/labeled maintenance dose after a response is achieved. Evidence: Some trial evidence exists for specific reduced maintenance doses (e.g., SURMOUNT-MAINTAIN 5 mg arm); does not generalize to arbitrary 'microdoses'.
- Slower titration. Extending the time spent at each dose step during dose escalation, usually to manage side effects. Evidence: Commonly used clinically; not the same as a fixed low 'microdose'; limited comparative trial evidence.
- Less-frequent dosing. Administering a dose at longer intervals than labeled (e.g., beyond weekly for a weekly product). Evidence: Hypothesis-generating case series and pharmacokinetic modeling only; not established for weight outcomes.
- Tapering / off-ramping. Gradually reducing dose or frequency when discontinuing, as opposed to abrupt stopping. Evidence: No universal schedule; withdrawal trials show weight regain after stopping; tapering outcomes not established.
- Provider-defined 'microdose'. A marketing/program term used by a telehealth provider for a low-dose plan; definitions vary by provider and are not standardized. Evidence: Commercial label, not a clinical protocol; each provider's definition must be read individually.
- Compounded individualized dose. A patient-specific dose prepared by a compounding pharmacy under a prescription; not an FDA-approved product. Evidence: Compounded drugs are not FDA approved; no premarket review of safety, effectiveness, or quality.
- Oral, sublingual, buccal, ODT, or troche product. Non-injectable formulations. One approved oral semaglutide exists (Rybelsus); compounded oral/sublingual/ODT products are separate and unproven. Evidence: Injectable trial evidence does not transfer to oral/sublingual/ODT; absorption for compounded oral products is generally unestablished.
- Standard compounded injection. A compounded injectable at a conventional (non-reduced) dose; not FDA approved. Evidence: Compounded; not premarket-reviewed; distinct from both approved injectables and 'microdose' plans.
- FDA-approved branded product. A manufactured, FDA-approved GLP-1 (e.g., Wegovy, Ozempic, Zepbound, Mounjaro, Rybelsus) with reviewed manufacturing and labeling. Evidence: Premarket-reviewed; clinical-trial evidence applies to the specific approved product and dose.
What the evidence shows
- Dose-response for the approved products is real: higher labeled doses generally produced more weight loss in STEP and SURMOUNT, with more side effects.
- Reduced maintenance dosing has specific, limited trial support.
- Discontinuation is followed by weight regain in withdrawal trials.
What the evidence does not show
- That a sub-therapeutic microdose delivers the trial weight-loss results.
- That less-frequent dosing maintains results — only weak case-series/PK signals exist.
- That compounded oral or sublingual 'microdoses' are absorbed adequately.
Risks specific to low-dose and compounded programs
The main risks are not exotic: dosing errors from units-versus-milligrams confusion when compounded concentrations change; unproven absorption for oral/sublingual products; and the assumption that 'less' is automatically 'safer' or 'as effective', which the evidence does not support. See the safety hub and units vs milligrams.
What it costs
Compounded low-dose programs are priced by business model — bundled, membership-plus-medication, or coaching-heavy — more than by the drug. Compare on effective monthly cost, not headlines; the cost hub and calculator normalize offers.
Frequently asked questions
Is microdosing the same as a starter dose?
No. A starter dose is the FDA-labeled low initial dose used before titration; a provider 'microdose' is a commercial plan that may or may not correspond to any labeled dose. The guide keeps them separate.
Is less-frequent dosing proven for maintenance?
No. Only weak case-series and pharmacokinetic modeling exist. It is a hypothesis, not an established maintenance strategy.
Can I get a microdosing schedule here?
No. A universal schedule would be unsafe given variable definitions and compounded concentrations. Dosing is an individual clinical decision.
Primary sources
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.